Literature DB >> 12970294

Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy.

Seema Kumar1, Rebecca S Bahn.   

Abstract

Graves' ophthalmopathy (GO) is an autoimmune disorder involving the adipose and connective tissues of the orbit. The study of cytokines present in these tissues may reveal the nature of the cells and immune responses involved in GO pathogenesis. In the current study, we performed relative quantification of the expression of cytokine genes in orbital adipose tissue from patients with GO (n = 6) and normal individuals (n = 2). Real-time RT-PCR was performed using fluorescent probes and primers for cytokines including IL-1 beta, IL-2, IL-4, IL-5, IL-8, IL-10, IFN-gamma, and TNF-alpha. Results showed IL-1 beta to be the gene having the greatest fold expression increase over normal in four of six patients. TNF-alpha was increased in all six GO patients. In addition, IL-8, IL-10, and IFN-gamma were increased in five of six GO patients. We found no evidence of either IL-4 or IL-5 expression in any of the GO or normal samples. The increased expression of the macrophage-derived cytokines IL-1 beta, TNF-alpha, and IL-10 suggests the presence of macrophage activation and ongoing antigen presentation within the orbit in GO. In addition, the overexpression of IFN-gamma, without evidence of IL-4 or IL-5 expression, supports the concept that cell-mediated, rather than humoral, immunity plays the predominant role in pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970294     DOI: 10.1210/jc.2003-030380

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

Review 2.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

4.  The tear cytokine profile in patients with active Graves' orbitopathy.

Authors:  Morgan Yang; Yvonne Chung; Stephanie Lang; Nobuyo Yawata; Lay Leng Seah; Audrey Looi
Journal:  Endocrine       Date:  2017-11-16       Impact factor: 3.633

Review 5.  Acute thyroid eye disease (TED): principles of medical and surgical management.

Authors:  D H Verity; G E Rose
Journal:  Eye (Lond)       Date:  2013-02-15       Impact factor: 3.775

Review 6.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

7.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 8.  Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Terry J Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-10       Impact factor: 3.243

9.  Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells.

Authors:  Zhiping Sun; Weixue Zhong; Xiang Lu; Bimin Shi; Yibei Zhu; Lei Chen; Guangbo Zhang; Xueguang Zhang
Journal:  J Clin Immunol       Date:  2008-08-14       Impact factor: 8.317

10.  Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.

Authors:  Teck Kim Khoo; Michael J Coenen; A Reagan Schiefer; Seema Kumar; Rebecca S Bahn
Journal:  Thyroid       Date:  2008-12       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.